CTOs on the Move

ImClone Systems

www.imclone.com

 
ImClone Systems is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.imclone.com
  • 440 Us Highway 22
    Bridgewater, NJ USA '08807
  • Phone: 908.541.8000

Executives

Name Title Contact Details

Similar Companies

Asthmatx

Asthmatx is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Practical Applications

Practical Applications is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orsini Healthcare

Orsini Healthcare is a Elk Grove Village, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DiaCarta

DiaCarta is a translational genomics and personalized diagnostics company that provides ultra-sensitive detection tools for cancer diagnosis, therapy identification and prognosis monitoring. Our mission is to provide ultra-sensitive and advanced technologies that will redefine the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world.

Code Biotherapeutics

Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to treat the untreatable and cure the incurable. Code Bio is developing highly targeted genetic medicines with its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with the delivery of genetic medicines. 3DNA offers unparalleled tissue and cell targeting specificity, improved bioavailability, capability to deliver large genetic payloads, potential ability to re-dose, and a scalable, modular, reproducible manufacturing process. Our 3DNA delivery platform is poised to transform the field of genetic medicines, enabling targeted delivery of gene therapy, RNAi and other genetic modalities. Currently we are advancing an internal pipeline of genetic medicines focused on select diseases without a cure (Duchenne`s Muscular Dystrophy and Type 1 Diabetes), as well as establishing partnerships to take forward programs in both rare and prevalent diseases.